GLP-1 Weight Loss Drugs Linked to Decreased Physical Activity

A recent study presented at the Endocrine Society’s annual meeting, ENDO 2026, reveals a counterintuitive trend among patients using GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro. While these medications are highly effective at inducing weight loss, researchers found that patients actually became less physically active after beginning treatment. By analyzing Fitbit data from over 750 participants, the study showed a measurable decline in both daily step counts and time spent in moderate-to-vigorous physical activity.

This discovery challenges the common assumption that shedding excess weight naturally encourages individuals to move more. The data indicated that average daily steps dropped from 5,047 to 4,487, while daily exercise duration decreased by approximately six minutes. These declines were particularly pronounced in male participants and those experiencing musculoskeletal pain, suggesting that the physiological changes induced by the drugs may not automatically translate into a more active lifestyle.

These findings carry significant implications for long-term health, particularly regarding body composition. Because GLP-1 medications are known to cause a reduction in lean muscle mass alongside fat loss, the concurrent decrease in physical activity is concerning. Muscle preservation is critical for metabolic health and physical function, meaning that exercise is not merely a secondary benefit but a necessary component of a successful treatment plan.

Ultimately, the study underscores the need for a more comprehensive approach to obesity management. Healthcare providers should not assume that weight loss alone will improve a patient's fitness levels. Instead, clinical protocols for patients on GLP-1 therapy should include targeted interventions that prioritize strength training and consistent physical activity to mitigate muscle loss and ensure that weight reduction leads to improved overall health rather than a sedentary lifestyle.